WallStreetZenWallStreetZen

NYSE: BHVN
Biohaven Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BHVN

Based on 13 analysts offering 12 month price targets for Biohaven Ltd

Min Forecast
$9.00+8.43%
Avg Forecast
$34.92+320.76%
Max Forecast
$75.00+803.61%

Should I buy or sell BHVN stock?

Based on 13 analysts offering ratings for Biohaven Ltd.

Strong Buy
Strong Buy
8 analysts 61.54%
Buy
3 analysts 23.08%
Hold
2 analysts 15.38%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BHVN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BHVN as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their BHVN stock forecasts and price targets.

BHVN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-13
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-11-05
UBS
Top 16%
85
Strong BuyMaintains$26.00+213.25%2025-09-16
Raymond James
Top 30%
71
Strong BuyInitiates Coverage On$75.00+803.61%2025-09-03
Leerink Partners
Top 11%
90
BuyMaintains$50.00+502.41%2025-08-12
Morgan Stanley
Top 8%
93
Strong BuyMaintains$54.00+550.60%2025-08-12
Bank of America
Top 19%
82
Strong BuyMaintains$49.00+490.36%2025-08-12

1 of 2

Forecast return on equity

Is BHVN forecast to generate an efficient return?

Forecast return on assets

Is BHVN forecast to generate an efficient return on assets?

Company
-60.03%
Industry
96.34%
BHVN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BHVN earnings per share forecast

What is BHVN's earnings per share in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
-$7.91
Avg 2 year Forecast
-$5.94
Avg 3 year Forecast
-$4.42

BHVN revenue forecast

What is BHVN's revenue in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
$4.7M
Avg 2 year Forecast
$101.6M
Avg 3 year Forecast
$286.1M

BHVN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BHVN$8.30$34.92+320.76%Strong Buy
TBPH$17.39$24.25+39.45%Strong Buy
CRMD$11.24$18.40+63.70%Buy
ABUS$4.52$5.00+10.62%Strong Buy
GHRS$14.00$31.00+121.43%Buy
View Top Biotech Stocks

Biohaven Stock Forecast FAQ

Is Biohaven Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 13 Wall Street analysts covering (NYSE: BHVN) stock is to Strong Buy BHVN stock.

Out of 13 analysts, 8 (61.54%) are recommending BHVN as a Strong Buy, 3 (23.08%) are recommending BHVN as a Buy, 2 (15.38%) are recommending BHVN as a Hold, 0 (0%) are recommending BHVN as a Sell, and 0 (0%) are recommending BHVN as a Strong Sell.

If you're new to stock investing, here's how to buy Biohaven stock.

What is BHVN's earnings growth forecast for 2025-2027?

(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.33%.

Biohaven's earnings in 2025 is -$780,110,000.On average, 20 Wall Street analysts forecast BHVN's earnings for 2025 to be -$837,017,882, with the lowest BHVN earnings forecast at -$905,633,193, and the highest BHVN earnings forecast at -$719,126,995. On average, 20 Wall Street analysts forecast BHVN's earnings for 2026 to be -$628,874,890, with the lowest BHVN earnings forecast at -$788,409,194, and the highest BHVN earnings forecast at -$519,060,753.

In 2027, BHVN is forecast to generate -$467,509,292 in earnings, with the lowest earnings forecast at -$720,979,461 and the highest earnings forecast at -$223,407,305.

What is BHVN's revenue growth forecast for 2025-2027?

(NYSE: BHVN) Biohaven's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.7%.

Biohaven's revenue in 2025 is $0.On average, 17 Wall Street analysts forecast BHVN's revenue for 2025 to be $493,708,443, with the lowest BHVN revenue forecast at $0, and the highest BHVN revenue forecast at $2,056,236,386. On average, 20 Wall Street analysts forecast BHVN's revenue for 2026 to be $10,758,059,403, with the lowest BHVN revenue forecast at $1,497,956,298, and the highest BHVN revenue forecast at $23,928,557,788.

In 2027, BHVN is forecast to generate $30,283,042,742 in revenue, with the lowest revenue forecast at $14,172,946,703 and the highest revenue forecast at $56,774,353,833.

What is BHVN's forecast return on assets (ROA) for 2025-2028?

(NYSE: BHVN) forecast ROA is -60.03%, which is lower than the forecast US Biotechnology industry average of 96.34%.

What is BHVN's Price Target?

According to 13 Wall Street analysts that have issued a 1 year BHVN price target, the average BHVN price target is $34.92, with the highest BHVN stock price forecast at $75.00 and the lowest BHVN stock price forecast at $9.00.

On average, Wall Street analysts predict that Biohaven's share price could reach $34.92 by Nov 13, 2026. The average Biohaven stock price prediction forecasts a potential upside of 320.76% from the current BHVN share price of $8.30.

What is BHVN's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: BHVN) Biohaven's current Earnings Per Share (EPS) is -$7.53. On average, analysts forecast that BHVN's EPS will be -$7.91 for 2025, with the lowest EPS forecast at -$8.56, and the highest EPS forecast at -$6.79. On average, analysts forecast that BHVN's EPS will be -$5.94 for 2026, with the lowest EPS forecast at -$7.45, and the highest EPS forecast at -$4.90. In 2027, BHVN's EPS is forecast to hit -$4.42 (min: -$6.81, max: -$2.11).

What is BHVN's forecast return on equity (ROE) for 2025-2028?

(NYSE: BHVN) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.